Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies

EMBO Molecular Medicine

Volumn 9, Issue 8, 2017, Pages 1067-1087

  Freedman, Joshua D ^a   Hagel, Joachim ^a   Scott, Eleanor M ^a   Psallidas, Ioannis ^b   Gupta, Avinash ^c   Spiers, Laura ^c   Miller, Paul ^c   Kanellakis, Nikolaos ^b   Ashfield, Rebecca ^d   Fisher, Kerry D ^a   Duffy, Margaret R ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

adenovirus; bispecific T cell engager; BiTE; oncolytic virus

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; ENADENOTUCIREV; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; TUMOR NECROSIS FACTOR; EPCAM PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; ONCOLYTIC VIRUS; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BINDING AFFINITY; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VIRUS REPLICATION; BIOPSY; CYTOTOXIC T LYMPHOCYTE; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES; TUMOR CELL CULTURE;

ADENOVIRUSES, HUMAN; ANTIBODIES, BISPECIFIC; BIOPSY; CD3 COMPLEX; EPITHELIAL CELL ADHESION MOLECULE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN BINDING; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 85026682258     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201707567     Document Type: Article

References (37)

1. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship between CD107a expression and cytotoxic activity. Cell Immunol 254: 149–154
2. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69: 4941–4944
3. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974–977
4. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77–89
5. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T et al (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43: 1129–1143
6. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 30: 798–807
7. Calvo EGMM, Cubillo A, Machiels J, Rottey S, Mardjuadi F, Geboes K, Salazar RBJ, Ellis C, Fisher K, Blanc C (2014) A phase 1 study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously – analysis of dose expansion and repeat cycle cohorts in patients with metastatic colorectal cancer (mCRC). Ann Oncol 25: lv361–lv372
8. Di Y, Seymour L, Fisher K (2014) Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther 21: 440–443
9. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100: 690–697
10. Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jakeman P, Chia SL, Brown A, Silva MA et al (2017) Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators. Mol Ther Oncolytics 4: 18–30
11. Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. Cancer Res 77: 2052–2063
12. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39: 44–51
13. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6: 343–345
14. Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y (2016) Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol 43: 638–646
15. de Gruijl TD, Janssen AB, van Beusechem VW (2015) Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 15: 959–971
16. Hermiston TW, Kuhn I (2002) Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9: 1022–1035
17. Illingworth S, Di Y, Bauzon M, Lei J, Duffy M, Alvis S, Champion B, Lieber A, Hermiston T, Seymour L et al (2017) Pre-clinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus. Mol Ther Oncolytics 5: 62–74
18. Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29: 6051–6063
19. Karlsson M, Nilsson O, Thorn M, Winqvist O (2008) Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry. J Immunol Methods 334: 122–133
20. Keller BA, Bell JC (2016) Oncolytic viruses-immunotherapeutics on the rise. J Mol Med (Berl) 94: 979–991
21. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119: 6226–6233
22. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K et al (2008) Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 3: e2409
23. Li GD, Kawashima H, Ogose A, Ariizumi T, Hotta T, Kuwano R, Urata Y, Fujiwara T, Endo N (2013) Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells. Cancer Sci 104: 1178–1188
24. Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN (2017) Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One 12: e0177810
25. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138–146
26. Nakamura K, Smyth MJ (2016) Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 95: 325–332
27. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43: 763–771
28. Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S et al (2015) FDA approval: blinatumomab. Clin Cancer Res 21: 4035–4039
29. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jager E, Cameron BJ, Lissin N et al (2006) Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176: 7308–7316
30. Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans-van den Brink JA, van der Poel K, Costa AI, van Els CA, van Baarle D et al (2015) Comprehensive analysis of the naturally processed peptide repertoire: differences between HLA-A and B in the immunopeptidome. PLoS One 10: e0136417
31. Seymour LW, Fisher KD (2016) Oncolytic viruses: finally delivering. Br J Cancer 114: 357–361
32. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154–5157
33. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493–2498
34. Weerasinghe P, Buja LM (2012) Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol 93: 302–308
35. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA (2005) BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10: 1237–1244
36. Yao X, Labelle M, Lamb CR, Dugan JM, Williamson CA, Spencer DR, Christ KR, Keating RO, Lee WD, Paradis GA et al (2013) Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. Int J Cancer 133: 2925–2933
37. Yuraszeck T, Kasichayanula S, Benjamin JE (2017) Translation and clinical development of bispecific T cell engaging antibodies for cancer treatment. Clin Pharmacol Ther 101: 634–645